Literature DB >> 20960094

A case of fugitive acromegaly, initially presented as invasive prolactinoma.

Jung Soo Lim1, Cheol Ryong Ku, Mi-Kyung Lee, Tai Seung Kim, Sun Ho Kim, Eun Jig Lee.   

Abstract

Fugitive acromegaly is most commonly caused by pituitary acidophil stem cell adenomas, and is characterized by a relatively short clinical history, a large and locally invasive tumor, and relatively low hormonal activity. Here, we report an unusual case of fugitive acromegaly that initially presented as invasive prolactinoma. A 48-year-old man with a huge pituitary mass extending to the suprasellar area was referred to our hospital in December 2007. He had undergone transsphenoidal surgery in November 1999 because of a large invasive prolactinoma. The tumor had grown progressively, despite therapy with dopamine agonists. Subtle features of acromegaly were noted and serum IGF-1 levels were high (733 ng/ml). An oral glucose tolerance test revealed that basal and nadir levels of growth hormone (GH) were 1.56 and 1 ng/ml, respectively. As a therapeutic trial, long-acting octreotide (20 mg IM, monthly) was added, and the tumor size markedly reduced within 6 months on magnetic resonance imaging examination. Immunohistochemical staining of the tumor tissue obtained at the surgery in 1999 showed positive staining for GH and prolactin (PRL). Double immunofluorescence staining showed a mixed positivity for GH and PRL in the majority of tumor cells; however, the two hormones colocalized in a minority of tumor cells, indicating that the tumor was composed of three different cell types (GH, PRL, and GH/PRL). The diagnosis of fugitive acromegaly was initially overlooked in this patient because of normal serum GH levels and a lack of acromegalic features, although histological evidence for GH production was present. IGF-1 determinations would be helpful for the diagnosis of fugitive acromegaly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20960094     DOI: 10.1007/s12020-010-9341-5

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  21 in total

1.  Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma.

Authors:  H G Maheshwari; T R Prezant; V Herman-Bonert; H Shahinian; K Kovacs; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

2.  Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.

Authors:  Marina Gradiser; Martina Matovinovic; Milan Vrkljan
Journal:  Croat Med J       Date:  2007-02       Impact factor: 1.351

3.  Effects of 17 beta-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: correlation with specific cellular receptors.

Authors:  B Caronti; G Palladini; M G Bevilacqua; E Petrangeli; B Fraioli; G Cantore; G Tamburrano; C M Carapella; M L Jaffrain-Rea
Journal:  Tumour Biol       Date:  1993

4.  PPAR-gamma receptor ligands: novel therapy for pituitary adenomas.

Authors:  Anthony P Heaney; Manory Fernando; Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 5.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

Review 6.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

7.  The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.

Authors:  Eleanor Gutteridge; Amit Agrawal; Robert Nicholson; Kwok Leung Cheung; John Robertson; Julia Gee
Journal:  Int J Cancer       Date:  2010-04-15       Impact factor: 7.396

8.  Sustained clinical inactivity and stabilization of GH/IGF-1 levels in an acromegalic patient after discontinuation of somatostatin analogue treatment.

Authors:  Avraam Avramidis; Stergios A Polyzos; Zoe Efstathiadou; Marina Kita
Journal:  Endocr J       Date:  2008-04-01       Impact factor: 2.349

9.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Authors:  B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

Review 10.  Future treatment strategies of aggressive pituitary tumors.

Authors:  Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more
  5 in total

Review 1.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

2.  The relationship between serum levels of prolactin and growth hormone in the early postnatal period.

Authors:  Jonathan Daliot; Tami Laron-Kenet; Mohammad Wattad; Anat Ben-Dor; Pearl Lilos; Zvi Laron
Journal:  Pediatr Res       Date:  2017-08-02       Impact factor: 3.756

3.  Primary hypothyroidism presenting as pseudoacromegaly.

Authors:  K V S Hari Kumar; Altamash Shaikh; Irfan Anwar; P Prusty
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

Review 4.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Authors:  W Saeger; J Honegger; M Theodoropoulou; U J Knappe; C Schöfl; S Petersenn; R Buslei
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

Review 5.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.